UK's GENinCode surges after nod to sell its products in US
03/01/2023 09:16
** Shares of GENinCode GENIG.L rise as much as 25% to 10p
** Co, focused on cardiovascular disease prevention,
receives licensing approval and clinical certification for its
Irvine laboratory in California
** Says approval marks a major milestone in the
commercialisation of the firm's polygenic products, which can
now be sold across U.S. and serviced from its California CLIA
lab
** Stock to log record intraday gains, if trend holds
** Up to last close, stock down ~76% in 2022
(Reporting by Prerna Bedi in Bengaluru)
((Prerna.Bedi@thomsonreuters.com; +91 98052 24616;))